IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Robert J. Chambers et al.

EXAMINER: Rita J. Desai

SERIAL NO.: 10/613,988

: ART UNIT: 1625

FILED: July 02,2003

FOR: Nicotinamide Biaryl Derivatives Useful

as Inhibitors of PDE4 Isozymes

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

Sir:

<u>Terminal Disclaimer</u> Under 37 C.F.R. §1.312(c)

Pfizer Inc., the owner of 100 percent interest in the instant patent application, hereby makes the following disclaimer.

The above-identified application has been provisionally rejected for obviousness-type double patenting over commonly owned US Patent Application No. 10/066,503, filed January 31, 2002. Applicants hereby disclaim the term of any patent issuing from the instant application which extends beyond the term of any US patent issuing from US Patent Application No. 10/066,503 or of any continuation or divisional applications thereof.

The owner hereby agrees that any patent granted on the instant application shall be enforceable only for and during the period that it and any patent issuing from US Patent Application No. 10/066,503 or continuation or divisional applications thereof are and remain commonly owned. Any patent granted on the instant application shall cease to be enforceable at the time that common ownership ceases, although any patent issuing from US Patent Application No. 10/066,503 or continuation or divisional applications thereof shall remain in force and be enforceable for any remainder of its statutory term as defined in 35 USC 154 to 156 and 173. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

The undersigned is an attorney of record.

Please charge the \$110.00 fee under 37 CFR 1.20(d) to Deposit Account No. 16-1445. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 16-1445. Two copies of this sheet are enclosed.

Date: July 6, a

Respectfully submitted,

Robert T. Ronaน

Attorney for Applicant(s)

Reg. No. 36,257

Pfizer Inc.

Patent Department, Box 8260-1611

Eastern Point Road Groton, CT 06340 (860) 441-5910